LENZ THERAPEUTICS, INC. Financing Cash Flow
LENZ THERAPEUTICS, INC. (LENZ) reported Financing Cash Flow of $409.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $395.00K, a 98.51% decline year-over-year.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $14.00K, a 68.18% decline year-over-year.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $122.61M, a 231249.06% increase year-over-year.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $598.00K, a 97.99% decline year-over-year.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $149.75M, a 24.75% decline from fiscal 2024.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $199.00M, a 146.59% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $80.70M, a 13417.59% increase from fiscal 2022.
- LENZ THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $597.00K, a 99.86% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $395.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $409.00K 10-Q · filed 2026-08-11 | $123.02M derived: sum of 3 quarters · filed 2026-08-11 | $123.62M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $14.00K 10-Q · filed 2026-05-11 | $122.63M derived: sum of 2 quarters · filed 2026-05-11 | $123.23M derived: sum of 3 quarters · filed 2026-05-11 | $149.72M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $122.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $123.21M derived: sum of 2 quarters · filed 2026-03-24 | $149.70M derived: sum of 3 quarters · filed 2026-08-11 | $149.75M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $598.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $27.09M derived: sum of 2 quarters · filed 2026-08-11 | $27.13M 10-Q · filed 2025-11-05 | $27.18M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $26.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $26.53M 10-Q · filed 2026-08-11 | $26.59M derived: sum of 3 quarters · filed 2026-08-11 | $56.40M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $44.00K 10-Q · filed 2026-05-11 | $97.00K derived: sum of 2 quarters · filed 2026-05-11 | $29.91M derived: sum of 3 quarters · filed 2026-05-11 | $27.78M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $29.87M derived: sum of 2 quarters · filed 2026-03-24 | $27.73M derived: sum of 3 quarters · filed 2026-03-24 | $199.00M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | $29.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $27.68M derived: sum of 2 quarters · filed 2025-11-05 | $198.95M 10-Q · filed 2025-11-05 | $197.04M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $169.13M 10-Q · filed 2025-07-30 | $167.22M derived: sum of 3 quarters · filed 2025-07-30 | $166.65M derived: sum of 4 quarters · filed 2025-07-30 | ||||
| 2024-03-31 | $171.27M 10-Q · filed 2025-05-07 | $169.36M derived: sum of 2 quarters · filed 2025-05-07 | $168.79M derived: sum of 3 quarters · filed 2025-05-07 | $168.79M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$2.48M derived: sum of 2 quarters · filed 2025-03-19 | -$2.48M derived: sum of 3 quarters · filed 2025-03-19 | $80.70M 10-K · filed 2025-03-19 | $190.00K 10-K · filed 2024-02-27 | |||
| 2023-09-30 | -$568.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$568.00K derived: sum of 2 quarters · filed 2024-11-06 | $82.61M 10-Q · filed 2024-11-06 | $124.00K 10-Q · filed 2023-11-13 | $82.86M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $83.18M 10-Q · filed 2024-08-14 | $116.00K 10-Q · filed 2023-08-14 | $83.42M derived: sum of 3 quarters · filed 2024-08-14 | $83.36M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $83.18M 10-Q · filed 2024-05-08 | -$8.00K 10-Q · filed 2023-05-11 | $83.42M derived: sum of 2 quarters · filed 2024-05-08 | $83.36M derived: sum of 3 quarters · filed 2024-05-08 | $83.78M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $185.00K derived: sum of 2 quarters · filed 2024-02-27 | $597.00K derived: sum of 3 quarters · filed 2024-02-27 | $597.00K 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | -$59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $353.00K derived: sum of 2 quarters · filed 2023-11-13 | $353.00K 10-Q · filed 2023-11-13 | $666.00K derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $412.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $412.00K 10-Q · filed 2023-08-14 | $725.00K derived: sum of 3 quarters · filed 2023-08-14 | $32.62M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $313.00K derived: sum of 2 quarters · filed 2023-05-11 | $32.20M derived: sum of 3 quarters · filed 2023-05-11 | $251.70M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $32.20M derived: sum of 2 quarters · filed 2023-03-20 | $251.70M derived: sum of 3 quarters · filed 2023-03-20 | $417.47M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | $31.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $251.39M derived: sum of 2 quarters · filed 2022-11-09 | $417.15M 10-Q · filed 2022-11-09 | $432.27M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $219.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $385.26M 10-Q · filed 2022-08-11 | $400.38M derived: sum of 3 quarters · filed 2022-08-11 | $400.34M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $165.77M 10-Q · filed 2022-05-12 | $180.89M derived: sum of 2 quarters · filed 2022-05-12 | $180.85M derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | $15.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $15.08M derived: sum of 2 quarters · filed 2022-03-21 | $30.08M 10-K · filed 2022-03-21 | |||||
| 2020-09-30 | -$42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $14.96M 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $15.00M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |